KVUE · 8-K · 20260806PR000141
Product Launch and Transition
Kenvue Inc. · 2026-08-06 · Importance 31 · Surprise 42 · No source text
The FDA approved Tylenol® with Naproxen, an OTC fixed-dose combination of acetaminophen and naproxen sodium. The product combines 650 mg of acetaminophen with 220 mg of naproxen sodium, begins working in under 30 minutes, and provides 12 hours of relief. Kenvue expects the product to become available soon at major U.S. retailers and has a three-year exclusivity period supported by eight clinical studies.
Key facts
- Kenvue introduced Codral Kids in Australia, the brand’s first range of products designed for children. source
- Tylenol with Naproxen combines 650 mg of acetaminophen with 220 mg naproxen sodium in one dose. source
- Tylenol with Naproxen begins working in under 30 minutes and provides relief for 12 hours. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | Kenvue introduced Codral Kids in Australia, the brand’s first range of products designed for children. |